StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Trading Down 3.5 %

Trevena stock opened at $1.93 on Friday. Trevena has a 12-month low of $1.13 and a 12-month high of $19.23. The firm has a market capitalization of $1.64 million, a price-to-earnings ratio of -0.03 and a beta of 1.02. The firm has a 50 day moving average of $3.89 and a 200 day moving average of $6.70.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($9.25) by $9.02. The firm had revenue of $0.33 million for the quarter. On average, analysts predict that Trevena will post -32.25 EPS for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.